naspcc_program_Layout 1 10/30/2026 3:17 PM Page 1

21ST ANNUAL MEETING & DINNER

NATIONAL ALLIANCE OF STATE PROSTATE CANCER COALITIONS

"MEANINGFUL SCIENCE AND PATIENT ADVOCACY"

November 13 - 15, 2026

Four Seasons Hotel, Washington, DC

22nd ANNIVERSARY

NASPCC

National Alliance of State
Prostate Cancer Coalitions



naspcc_program_Layout 1 10/30/2026 3:17 PM Page 1

WELCOME TO THE 21ST ANNUAL MEETING!

Friday through Sunday
November 13 - 15, 2026

Welcome to the 21st Annual Meeting of the National Alliance of State Prostate Cancer Coalitions! We have accomplished so much since we began in 2004, and we are growing again! This year's Annual Meeting is all about "Meaningful Science and Patient Advocacy". You will learn both over this Weekend.

You will hear about our Annual Meetings, our Laminates, our PROSTATEPEDIA Magazine and weekly PROSTATEPEDIA DIGEST. And now you will learn that NASPCC and Europa Uomo (the European Prostate Cancer Coalition) are spearheading the creation of a world prostate cancer coalition as yet unnamed, but tentatively called the International Union of Prostate Cancer Coalitions (IUPCC). The name hearkens to the UICC (the Union for International Cancer Control).

NASPCC is all about education, about the early detection of potentially lethal disease, and about helping men and their families and significant others achieve the best quality of life and high standards of survivorship. Our Mission includes our aim to develop and to mentor state prostate cancer coalitions, associations, foundations, and other organizations to help men (1) have better dialogue with (and help) other patients, and (2) have better informed discussions with their physicians which will lead to more meaningful shared decision-making.

We hope you come away from this Annual Meeting better educated about prostate cancer and better equipped to use that knowledge to advocate for prostate cancer patients and their quality of life. Much work remains.

Please use this weekend to listen, to participate in sessions, to network, to trade stories and ask questions. The sharing of best practices with our Scientific Sessions tomorrow and Sunday (morning) will hopefully lead us to better Advocacy Sessions on Sunday to help state prostate cancer organizations and prostate cancer patients, individually.

Sincerely,



Merel Grey Nissenberg,
President, "The Prostate Cancer Alliance" (NASPCC)

naspcc_program_Layout 1 10/30/2026 3:17 PM Page 2

21st ANNUAL MEETING
NATIONAL ALLIANCE OF STATE PROSTATE CANCER COALITIONS

"MEANINGFUL SCIENCE AND PATIENT ADVOCACY"

FRIDAY NOVEMBER 13, 6:30 PM - 9:30 PM RECEPTION
Special Remarks by *James Gulley, MD, PhD, National Institutes of Health
FOUR SEASONS HOTEL, WASHINGTON, DC

SATURDAY, NOVEMBER 14

AGENDA

SESSION NAME	TIME	
BREAKFAST	**8:00 – 8:45**	
1. Welcome and Introductions	9:00-9:15	*Merel Nissenberg, Esq. *Vincent Laudone, MD Emeritus Faculty, Memorial Sloan Kettering, New York
2. Expanding Active Surveillance to Patients with Favorable Intermediate Risk	9:15-9:35	*James Eastham, MD Chief, Urology Service Memorial Sloan Kettering, New York
3. Genetics and Genomics for Risk Assessment: Germline and Somatic Testing	9:35-10:00	*Jeremiah Wala, MD Dana-Farber Cancer Institute (Harvard), Boston, Massachusetts
4. Neoadjuvant Approaches to High-Risk Prostate Cancer	10:00-10:25	*Christopher Barbieri, MD, PhD Weill-Cornell, New York
BREAK		
5. What's New in Radiation Therapy	10:45-11:10	*Curtiland Demille, MD Johns Hopkins University School of Medicine, Washington, DC
6. Evaluation of a Rising PSA After Radiation Therapy	11:10-11:35	*James Eastham, MD Chief, Urology Service Memorial Sloan Kettering, New York
7. ABC's of Hormonal Therapy	11:35-12:00	*Mark Markowski, MD Johns Hopkins, Baltimore
LUNCH	**12:00-12:55**	
8. New Nomenclature from PCa Working Group 4	1:00-1:20	*Andrew Armstrong, MD Duke Medical Center, Durham, North Carolina

naspcc_program_Layout 1 10/30/2026 3:17 PM Page 3

9. Transdermal Estradiol Androgen Deprivation Therapy: Science & Quality of Life	1:30-1:50	*Paul Schellhammer, MD Urologic Oncologist, Virginia Beach, Virginia
10. Precision Medicine Approaches to Treating Men With Metastatic Androgen Pathway Modulator Naive/Sensitive Prostate Cancer; PSMAddition, Capitello, and Talapro-3 Trials	1:50-2:20	*Andrew Armstrong, MD, ScM, FACP Duke Medical Center, Durham, North Carolina
11. Radioligand Therapy Primer including PSMA-617, PSMA-I&T, and Updates on Radiopharmaceuticals	2:20-2:45	*Scott Tagawa, MD New York Presbyterian-Weill Cornell, New York
12. Shifting Landscape for Metastatic Hormone-Sensitive Prostate Cancer	2:45-3:00	*Mark Markowski, MD Johns Hopkins, Baltimore
Break	**3:00-3:10**	
13. Radium-223 Updates; new PSMA Agents; Non-AR Therapty for Castrate-Resistant Prostate Cancer	3:15-3:40	*Scott Tagawa, MD New York Presbyterian-Weill Cornell, New York
14. Biomarker-Directed Therapies in Advanced Disease	3:45-4:10	*Christopher Barbieri, MD, PhD Weill-Cornell, New York
15. General Guidelines for Good Health!	4:10-4:30	*Vincent Laudone, MD Emeritus Faculty, Memorial Sloan Kettering, New York
16. Car-T Cell Therapy in Prostate Cancer	4:30-5:00	*Saul Priceman, PhD Keck School of Medicine, USC, Los Angeles
17. T-Cell Engagers	5:00-5:30	*Sumit Subudhi, MD, PhD UT MD Anderson Cancer Center, Houston, Texas
ADJOURN *****		
Dinner and cocktails start at	**6:30 P.M.**	

DINNER PRESENTATION: "THE POWER AND PROMISE OF NON-INVASIVE LIQUID BIOPSIES TO GUIDE PROSTATE CANCER DIAGNOSIS AND TREATMENT"

Peter Nelson, MD



Peter Nelson, MD, is a physician scientist focused on the pathobiology of prostate cancer. He is a Professor in the Divisions of Human Biology and Clinical Research at the Fred Hutchinson Cancer Center and Director of the Sloan Precision Oncology Institute; and he is a Professor in the Departments of Medicine, Genome Sciences and Pathology at the University of Washington. He co-leads the Fred Hutch NCI Comprehensive Cancer Center's Prostate Cancer Program and is PI of the Pacific Northwest Prostate Cancer SPORE. Dr. Nelson's research focuses on androgen receptor function as a lineage oncogene in prostate cancer; assessments of cancer genomes and epigenomes with respect to gene regulation/therapeutic targets, and tumor microenvironments as mediators of treatment resistance.

naspcc_program_Layout 1 10/30/2026 3:17 PM Page 4

SUNDAY, NOVEMBER 15

AGENDA

SESSION NAME	TIME	
BREAKFAST	**8:00-8:45**	
Update on the PCMRP		*Mark Vieth Senior Vice President, CRD Associates
18. **Panel:** "The Path Forward for Immunotherapy in Patients With Prostate Cancer"	9:00-9:35	*Peter S. Nelson, MD The Fred Hutchinson Cancer Center *Saul Priceman, PhD Keck School of Medicine, USC, Los Angeles *Sumit Subudhi, MD, PhD UT MD Anderson Cancer Center, Houston, Texas *Bilal Siddiqui, MD UT MD Anderson Cancer Center, Houston, Texas
19. Bone Health in Prostate Cancer Management	9:35-9:55	*Jeff Michalski, MD, MBA Washington University, St. Louis, Missouri
20. Update on Lifestyle Factors For the Prevention And Treatment of Prostate Cancer	9:55-10:15	*Joseph Scherger, MD, MPH Restore Health, Indian Wells, California
21. Improving your Patient Advocacy Skills	10:15-10:30	*Robert Ginyard Speaker and Author, Baltimore, Maryland
22. State Coalition Activities and Patient Presentations: Presented by NASPCC's Awareness and Education Committee	**10:30-11:30**	Panels TBD
23. Elections and Committee Choices	**11:30-12:30**	
24. State Coalition Development Committee	**12:30-1:00**	***Beth Bridges** ***David Sauls**
25. Wrap-Up and Adjournment	**1:00-1:05**	***Merel Nissenberg, Esq.**

21st ANNUAL MEETING ADJOURNS

naspcc_program_Layout 1 10/30/2026 3:17 PM Page 5

ABOUT NASPCC – "THE PROSTATE CANCER ALLIANCE"

The National Alliance of State Prostate Cancer Coalitions (NASPCC) is a 501(c)(3), not-for-profit organization, with an extensive network and national outreach through many state prostate cancer organizations and individuals. We are an Alliance comprised of many entities, including state prostate cancer coalitions, foundations, associations, and others who are interested in helping to save the lives of men with prostate cancer.

NASPCC – "The Prostate Cancer Alliance" was formed in October 2004 to serve as an umbrella organization in which state prostate cancer organizations could participate and help generate "strength in numbers". We have become a large critical mass and voice for prostate cancer patients and their families.

We publish PROSTATEPEDIA Magazine and a weekly PROSTATEPEDIA DIGEST, a compendium of the most current curated articles, abstracts, and press releases. Subscriptions are free and these are sent to 20,000+ people on our Subscription List. The Magazines are archived on our www.naspcc.org website.

We advocate for Informed Decision-Making in prostate cancer, and we disseminate durable, laminated 2-sided education tools for both patients AND for physicians. There are 6 completed Laminates and 5 in queue. We hold an Annual Meeting to enhance education and to share best practices with patients across the country. The resources we disseminate make their way through to the states and reach down through to the local levels, including support groups and individuals who do not participate in those groups. We advocate for the arly detection of potentially lethal disease.

We actively provide, through our participating organizations: support groups, educational forums, Webinars, Workshops, prostate cancer information, and awareness and educational activities. Our website www.naspcc.org is very dynamic and we have an active Facebook Page "National Alliance of State Prostate Cancer Coalitions" as well.

We advocate for the highest quality of life for prostate cancer patients and their families.


We have an Advisory Board comprised of influential and respected physicians, scientists and researchers.

We are many states strong and growing. We are "The Prostate Cancer Alliance"!

EDUCATIONAL OBJECTIVES

At the conclusion of NASPCC's 21st Annual Meeting, attendees will have learned about many of the basics of prostate cancer, about testing and therapies, about survivorship and quality of life considerations. NASPCC is here to help state prostate cancer organizations and the people who lead them, especially patients, advocate for themselves and for fellow patients. So too, we are here to help advocates who are interested in improving these metrics for prostate cancer patients and their families. Our theme this year, "Meaningful Science and Patient Advocacy" serves both purposes. We also want to improve access to care and to appropriate care whether one receives treatment in an academic medical center or at a small community clinic. We hope after this Annual Meeting you will be better empowered to make meaningful, informed, individualized decisions with your physicians, and will be better equipped to help other patients through your state organizations.

ABOUT NASPCC – PROSTATEPEDIA



Prostatepedia features informal conversations with doctors, patients, and activists about prostate cancer about prostate cancer. Each Issue tackles a different topic facing prostate cancer patients today—from how imaging has impacted treatment to dealing with erectile dysfunction after radiation or surgery to the evolving field of immunotherapy.

Prostatepedia Magazine (eight times a year) and the weekly **Prostatepedia Digests** became part of NASPCC starting with the August 2020 Issue of the magazine.

Here are the most recent PROSTATEPEDIA Magazine Issues (Please see www.naspcc.org for prior Issues):

Fall 2026 - *Androgen Receptor Pathway Inhibitors*
Prostatepedia Magazine - Vol 8 No. 2 - Flipping Book format:
https://online.flippingbook.com/link/362010/

Spring 2026 - *Immunotherapy + Prostate Cancer*
Prostatepedia Magazine - Vol 8 No. 1 - Flipping Book format:
https://online.flippingbook.com/link/677451/

October 2025 - *Radiation Therapy*
Prostatepedia Magazine - Vol 7 No. 7 - Flipping Book format:
https://online.flippingbook.com/view/119639388/

December 2023 - *Side Effects*
Prostatepedia Magazine - Vol 7 No. 5 - Flipping Book format:
https://online.flippingbook.com/view/76683675/

October 2023 Special Issue - *Black Men + Prostate Cancer*
Prostatepedia Magazine - Vol 7 Special Issue- Flipping Book format:
https://online.flippingbook.com/view/707889051/

July - August 2023 - *Testing*
Prostatepedia Magazine - Vol 7 No. 4 - Flipping Book format:
https://online.flippingbook.com/view/187941146/

May - June 2023 - *New Directions in Advanced Prostate Cancer*
Prostatepedia Magazine - Vol 7 No. 3 - Flipping Book format:
https://online.flippingbook.com/view/150884930/


Please use this link to Subscribe to Prostatepedia:
https://mailchi.mp/c98f8914f351/prostatepedia-sign-up

Or scan this QR Code:

naspcc_program_Layout 1 10/30/2026 3:17 PM Page 7

NATIONAL ALLIANCE OF STATE PROSTATE CANCER COALITIONS

EXECUTIVE COMMITTEE*



Merel Nissenberg, Esq. (California)
President, National Alliance of State Prostate Cancer Coalitions

Merel Grey Nissenberg, Esq. is a medical malpractice attorney in Los Angeles handling cases around the country, and she is President of three non-profits in healthcare: the National Alliance of State Prostate Cancer Coalitions (NASPCC); the California Prostate Cancer Coalition (CPCC), both of which she co-founded; and the Clifton F. Mountain Foundation for Education & Research in Lung Cancer. She is a member of two National Cancer Institute SPORES (one in Prostate Cancer at UCLA, one in Lung Cancer at M. D. Anderson Cancer Center), and she is on the UCLA SPORE Executive Committee. She is also the Advocate for the Canary Foundation/PASS Trial at Stanford (Prostate Active Surveillance) and is part of a PCORI Grant with UCLA dealing with decision aids in prostate cancer. Additionally, through her consulting group Informed Health Consulting she and her partner help accrue patients to Clinical Trials and also create Patient Ambassador Programs and Roundtables. Merel has been actively involved for almost ten years as one of three national Patient Advocates for the Early Detection Research Network (EDRN) of the National Cancer Institute, handling three of the four Collaborative Groups: GU Cancers, GYN Cancers, and Lung Cancer. In her law practice she has represented many cancer patients and has advocated for them and for their families. Merel is extremely interested in the early detection of cancers when they are still curable and is dedicated to improving the lives of patients, including those as-yet-undiagnosed.



Anthony Minter (South Carolina)
Treasurer, National Alliance of State Prostate Cancer Coalitions

Anthony Minter has been involved with Prostate Cancer Advocacy since 2012. As a Survivor, he made it his mission to provide support, education and awareness within his community and throughout the nation. Tony was the leader of the Columbia Chapter of UsToo International and is a Consumer Advocate for Zero Prostate Cancer. Recently, he has been selected to serve on the Executive Board of the National Alliance of State Prostate Cancer Coalitions (NASPCC) and is the current Treasurer. He has participated in numerous health fairs and information sessions concerning prostate cancer and has been a link between the patients, their families and their physicians. He is a Certified Professional Executive Coach, specializing in Relationships, Leadership, Career and life. Tony was also selected to be a Consumer Reviewer for the Congressionally Directed Medical Research Program (CDMRP), responsible for screening applications for research grants aimed at finding new treatment therapies, creating better detection tools and decreasing the Prostate Cancer health disparity in men of African descent.



Bruce Williams (Arizona)
Secretary, National Alliance of State Prostate Cancer Coalitions

Bruce Williams is past-president and a current director of the all-volunteer Arizona Prostate Cancer Coalition, Inc., an inclusive statewide nonprofit 501(c)(3) organization promoting awareness, education, early detection, effective treatment, and support for prostate cancer patients, their families, and caregivers. The Coalition is a proud participant in the National Alliance of State Prostate Cancer Coalitions.

Bruce retired from a tier one financial institution in 2016 as Vice President and Marketing Manager after 44 years with the firm.

Bruce is focused on making prostate cancer awareness and early detection an Arizona public health priority. In allied efforts, the Arizona Coalition has successfully advocated for State step therapy reform and biomarker testing legislation, and is currently advocating for Arizona's PSA screening legislation, together with passage of the Safe Step Act, the PSA Screening for HIM Act, and pharmacy benefit manager (PBM) reform pending before Congress. He is a participant in the Arizona Cancer Coalition and member of ACS CAN.

Bruce is married to Linda, and together they enjoy travel and vintage sports cars.



Chris Collier (Arkansas)
Director at Large, National Alliance of State Prostate Cancer Coalitions

Chris Collier joined the Arkansas Prostate Cancer Foundation (APCF) in February 2019 as Executive Director, bringing over thirty years of experience in business, education, and nonprofit leadership to the position. He has served on and chaired numerous nonprofit boards throughout central Arkansas. Professionally, prior to joining APCF, he served as the Director of Organizational Development for Arkansas Teacher Corps, a non-profit arm of the College of Education and Health Professions at the University of Arkansas, Fayetteville.

As APCF's Executive Director, Chris has the experience and perspective to guide the organization as it continues to expand its depth and breadth across the state of Arkansas. He provides daily leadership for his staff and drives relationship building statewide and beyond with patients, supporters, and stakeholders. A frequent speaker and presenter, he leads various organizational and educational outreach activities. In addition, he oversees strategic planning initiatives in support of the continued growth and development of the foundation. Under his leadership, the APCF has expanded their services and reach to previously unserved areas of Arkansas, developed strategic partnerships with a large number of entities heretofore untapped, implemented

continued on next page

naspcc_program_Layout 1 10/30/2026 3:17 PM Page 8

Chris Collier Continued

new patient and donor databases for the first time in the foundation's 25-year history, and installed streamlined technology capabilities to provide greater efficiencies. Chris was recently elected Chairperson of the Arkansas Cancer Coalition's (ACC) state board of directors and is a member of the National Alliance of State Prostate Cancer Coalitions (NASPCC), Board of Directors, having begun his term in 2023, and serves on their Executive Committee. Additionally, Chris has been selected to serve on the national American Cancer Society Roundtable planning committee

A native Arkansan raised in Hot Springs; Chris earned his Bachelor of Arts in political science from Hendrix College in Conway.

Chris has two sons and a stepdaughter, and four grandchildren. He and his wife, Brenda, live in Conway, Arkansas.



LaTanya Patton (Missouri)
Vice President, National Alliance of State Prostate Cancer Coalitions

LaTanya currently serves as the President and CEO of Missouri Prostate Cancer Alliance (MoPCA) which she co-founded 2013. In addition to her professional work, she is the primary caregiver for her mother who is stricken with Alzheimer's disease. LaTanya is a brain aneurysm survivor and supports the University of Kansas Health System Brain Aneurysm support group.

Prior to Missouri Prostate Cancer Alliance, she worked for Blue Cross and Blue Shield of Kansas City; Heart to Heart International – assigned to the country of Haiti; served as President and CEO of a small minority agency; Vice-President of Community Relations of MAST Ambulance and worked in various capacities for the City of Kansas City Missouri for 16 years including the Health Department before leaving to furthering her professional career.

LaTanya's community service activities include serving as an Ambassador for American Heart Association, The Mayor's Commission on AIDS/HIV (TGA), Ivy Community Service and Education Foundation, Swope Ridge Geriatric Center Board of Directors. She serves on the Board of Directors of NASPCC - Director at Large. LaTanya has been an active member of Alpha Kappa Alpha Sorority Incorporated for 34 years and is the immediate past President her chapter.

LaTanya has earned a Bachelor of Science in Business Administration from Lincoln University, Jefferson City, Missouri and is pursuing a Master in Business Administration from the University of Phoenix with an emphasis in organizational development and non-profit leadership. In addition, LaTanya considers herself a consistent leaner and is completing a teaching certification program at Western Bible College in Christian Education.

She has been a devoted member of her church in Kansas City, Missouri for the past 35 years where she serves as Culinary Leader, Youth Director and Vacation Bible School Director. She wants you to know that she is a "CHILD OF THE KING." She has received numerous awards and recognitions.

LaTanya is happily married to Frederick Patton and has two beautiful daughters, Lauren Patton, and Logan Patton. In her spare time, she enjoys reading, shopping, participating in community service activities with the sorority, volunteering and traveling with her family.

BOARD OF DIRECTORS 2025-2026

Merel Nissenberg	California	President
LaTanya Patton	Missouri	Vice President
Tiffany Razzo	Texas	Secretary
Tony Minter	Illinois	Treasurer
Chris Collier	Arkansas	Director-At-Large
Elizabeth (Beth) Bridges	Louisiana	Member
Paul Kradel	West Virginia	Member
Eivind Oland	South Dakota	Member
Rob Johnson	Wyoming	Member
David Sauls	Delaware	Member
Renee Savickas	Colorado	Member
Victor Taylor	North Carolina	Member
Bruce Williams	Arizona	Member
Darrell Wilson	Idaho	Member
Cheryl Cropp	Georgia	Member
Jon Sellers	Minnesota	Member
Ullyses Wright	Kansas	Member
Mark Harris	Michigan	Member
Deron Bryant	South Carolina	Member

naspcc_program_Layout 1 10/30/2026 3:17 PM Page 9

"Reaching Thousands of Prostate Cancer Patients and their Families Across the U.S. Since 2004"

MISSION STATEMENT

NASPCC is a nation-wide organization, comprised of state prostate cancer coalitions, dedicated to saving men's lives and enhancing the quality of life of prostate cancer patents and their families, through awareness and education and the development of a public policy network.

LEADERSHIP

NASPCC has an elected Board of Directors made up of State Representatives, which meets four times a year; and a Standing Executive Committee which meets monthly, composed of the four Officers and an elected Director-at-Large. Eight Advisory Committees were formed in November 2017 to help accomplish the goals of the Strategic Plan adopted in July 2017. In September 2018, the Executive Committee created a Standing Committee, chaired by Tom Kirk, to monitor and strengthen the progress of these **Eight Advisory Committees:**

Advocacy and Public Policy, Chair: Paul Kradel

Annual Meeting Committee, Chair: Merel Grey Nissenberg

Budget Committee, Chair: Tony Minter

Communications Committee, Chair: Renee Savickas/Fran Franklin

Education and Awareness Committee, Chair: Jon Sellers

Fundraising Committee, Chair: Merel Grey Nissenberg

Medical Advisory Committee, Chair: Michael Zaragoza, MD

State Coalition Development Committee, Chair: Beth Bridges/David Sauls

REACHING PATIENTS AND THEIR FAMILIES

NASPCC supports the development of state prostate cancer organizations, each of which is comprised of patient networks, individuals, and support groups. NASPCC through its Annual Meeting, webinars and other activities shares prostate cancer information with all of its participating state prostate cancer organizations, and this material is then disseminated to patients and their families, demonstrating the breadth and depth of our reach. NASPCC also helps equip patients and their families to actively engage in the prostate cancer cause.

THE NASPCC ANNUAL MEETING

The Annual Meeting pulls together leaders in the rapidly developing field of prostate cancer – patients and families, researchers, practitioners, and people interested in the disease – who want to share, learn and lead. The patient community is unique and the contemporary overview in the Take Home Messages from the Annual Meeting allows them to become empowered to do things locally. NASPCC creates support and a forum to enrich and rejuvenate these individuals and state organizations.

naspcc_program_Layout 1 10/30/2026 3:17 PM Page 10

Peter Nelson, MD
Award For Excellence in
Prostate Cancer Research, Helping Patients



Peter Nelson, MD, is a physician scientist with a research and clinical focus centered on the pathobiology of prostate cancer. Dr. Nelson is a Professor in the Divisions of Human Biology and Clinical Research at the Fred Hutchinson Cancer Center and Director of the Sloan Precision Oncology Institute. He is a Professor in the Departments of Medicine, Genome Sciences and Pathology at the University of Washington. He co-leads the Fred Hutch NCI Comprehensive Cancer Center's Prostate Cancer Program and is PI of the Pacific Northwest Prostate Cancer SPORE. Dr. Nelson's research involves several domains relevant to prostate cancer development and treatment at the interface of basic and applied science. Areas of focus include studies of androgen receptor function as a lineage oncogene in prostate cancer; assessments of prostate cancer genomes and epigenomes with respect to gene regulation and therapeutic targets, and analyses of tumor microenvironments as mediators of treatment resistance.

naspcc_program_Layout 1 10/30/2026 3:17 PM Page 11



JAMES WEST SPIRIT AWARD

MICHAEL ZARAGOZA, MD
Urology Associates, Dover, Delaware; President, Delaware Urological Association; & President, Delaware Prostate Cancer Coalition



The **James West Spirit Award** honors individuals who exemplify exceptional dedication, leadership, and service in advancing the mission and spirit of NASPCC.

Dr. Zaragoza obtained his undergraduate degree from Dartmouth College (1983) and MD from Jefferson Medical College (1987). He completed his Urology residency at the University of Michigan (1993), and has been employed in a group private practice, Urology Associates for Delaware, in Dover, Delaware since 1993.

His current academic appointments include Clinical Assistant Professor of Surgery (Urology) at Drexel University College of Medicine, and Clinical Assistant Professor of Surgery at the Philadelphia College of Osteopathic Medicine. Dr. Zaragoza presently serves as President of the Delaware Urological Society and as President of the Delaware Prostate Cancer Coalition (DPCC). He joined his urologist father Ralph Zaragoza (former DPCC president) in 1993, and they practiced together for 8 years.

After serving as Delaware's representative to NASPCC for many years, Dr. Zaragoza has now skillfully and sensitively assisted and moderated patient, survivor, and family panels for many NASPCC Annual Meetings. He has always graciously and without hesitation donated time to NASPCC and to prostate cancer patients and their families.

OUTSTANDING PROSTATE CANCER ORGANIZATION

Chris Collier, Arkansas
THE ARKANSAS PROSTATE CANCER FOUNDATION



Chris Collier joined the Arkansas Prostate Cancer Foundation (APCF) in February 2019 as Executive Director, bringing over thirty years of experience in business, education, and nonprofit leadership to the position. He has served on and chaired numerous nonprofit boards throughout central Arkansas. Professionally, prior to joining APCF, he served as the Director of Organizational Development for Arkansas Teacher Corps, a non-profit arm of the College of Education and Health Professions at the University of Arkansas, Fayetteville.

As APCF's Executive Director, Chris has the experience and perspective to guide the organization as it continues to expand its depth and breadth across the state of Arkansas. He provides daily leadership for his staff and drives relationship building statewide and beyond with patients, supporters, and stakeholders. A frequent speaker and presenter, he leads various organizational and educational outreach activities. In addition, he oversees strategic planning initiatives in support of the continued growth and development of the foundation. Under his leadership, the APCF has expanded their services and reach to previously unserved areas of Arkansas, developed strategic partnerships with a large number of entities heretofore untapped, implemented new patient and donor databases for the first time in the foundation's 25-year history, and installed streamlined technology capabilities to provide greater efficiencies. Chris was recently elected Chairperson of the Arkansas Cancer Coalition's (ACC) state board of directors and is a member of the National Alliance of State Prostate Cancer Coalitions (NASPCC), Board of Directors, having begun his term in 2023, and serves on their Executive Committee. Additionally, Chris has been selected to serve on the national American Cancer Society Roundtable planning committee

A native Arkansan raised in Hot Springs; Chris earned his Bachelor of Arts in political science from Hendrix College in Conway.

Chris has two sons and a stepdaughter, and four grandchildren. He and his wife, Brenda, live in Conway, Arkansas.

naspcc_program_Layout 1 10/30/2026 3:17 PM Page 12

NATIONAL ALLIANCE OF STATE PROSTATE CANCER COALITIONS 21ST ANNUAL MEETING FACULTY BIOS



Andrew Armstrong, MD, ScM, FACP
Professor of Medicine, Surgery, Pharmacology and Cancer Biology and Director of Research
Duke Cancer Institute's Center for Prostate and Urologic Cancer

Dr. Andrew Armstrong is the George Barth Geller Distinguished Professor for Research in Cancer and is a tenured Professor of Medicine, Urology, Pharmacology and Cancer Biology at Duke University. He also serves as the Director of Research for the Duke Cancer Institute's Center for Prostate and Urologic Cancer. He is a medical oncologist and internationally recognized expert in experimental therapeutics and biomarker development in genitourinary cancers, particularly in prostate cancer. He trained at Duke as a biomedical engineer, received his medical degree at the University of Virginia, medicine residency training at the University of Pennsylvania, fellowship and public health clinical investigation training at Johns Hopkins and the Bloomberg School of Public Health, and joined Duke's faculty in 2006.

As a clinical and translational investigator, he is focused on experimental therapeutics for patients with advanced genitourinary malignancies, particularly with a focus on prostate and kidney cancer and the investigation of biomarkers of response and benefit both in the laboratory and in the clinic. He is funded by the US Department of Defense, PCF/Movember, and the NIH for his work on hormone therapy resistance and lineage plasticity as well as circulating tumor cell biology and liquid biopsy approaches to precision medicine in prostate cancer. He led the development of enzalutamide and FDA approval for men with metastatic prostate cancer and studies hormone resistance in the laboratory and treatments to overcome resistance in the clinic. He led the development of abiraterone plus olaparib in BRCA mutated mCRPC and its 2024 FDA approval. He was a Prostate Cancer Foundation, AACR, and ASCO Young Investigator Award recipient. He co-chairs Prostate Cancer Working Group 3 and 4 which establishes guidelines for clinical research in advanced prostate cancer and was a leading writing member of the NCCN Prostate Cancer panel for 15 years for national clinical guidelines on the treatment of men with prostate cancer.

He has authored over 450 peer-reviewed publications as well as numerous chapters, reviews, and abstracts. He leads a team at Duke of over 40 research nurses, coordinators, data managers, regulatory specialists, scientists, and investigators dedicated to discovery science in GU cancers in the laboratory and treatment science in the clinic. He is a mentor to many students, post-docs, and fellows and participates in the ASCO mentoring program. As a multi-R01 funded clinical-translational investigator, he has mentored over 25 medical oncology fellows and junior faculty, and many residents and students both in the clinical, for clinical trials, and for laboratory training.



Christopher Barbieri, MD, PhD
Associate Professor of Urology & Urologic Oncology, Weill Cornell

Christopher Barbieri, MD, PhD is Associate Professor of Urology, Associate Professor of Cell and Developmental Biology, and the Peter M. Sacerdote Distinguished Associate Professor in Urologic Oncology at Weill Cornell Medicine and NewYork-Presbyterian Hospital. His clinical practice focuses on prostate cancer, and his long-term goal is using molecular information to improve the care of prostate cancer patients. Dr. Barbieri received his undergraduate degree from Dartmouth College and then attended Vanderbilt University School of Medicine, where he obtained both his MD and PhD degrees. He then completed both his Urology Residency and Urologic Oncology Fellowship at Weill Cornell Medical College. Dr. Barbieri's research focuses on improving molecular classification of prostate cancer and identifying novel drivers, defining the signaling pathways and biology underlying distinct subtypes of the disease, and exposing new therapeutic avenues. His work has led to recognition and awards from the Prostate Cancer Foundation, AACR, AAGUS, Urology Care Foundation, SBUR, SUO, and Damon Runyon Cancer Research Foundation, and election to ASCI.



Curtiland Deville, MD
Professor of Radiation Oncology and Molecular Radiation Sciences
Johns Hopkins Proton Therapy Center
Clinical Director and Chair of Sibley Radiation Oncology

Dr. Curtiland Deville is a Professor in the Department of Radiation Oncology and Molecular Radiation Sciences at the Johns Hopkins University School of Medicine. He serves as Medical Director of the Johns Hopkins Proton Therapy Center and Clinical Director and Chair of Sibley Radiation Oncology.

Dr. Deville's clinical expertise involves treating patients with prostate cancer. His funded research interests include improving tumor targeting and assessing toxicity profiles using modern radiation techniques including proton therapy. He has co-authored over 200 peer-reviewed publications, including the first experience and outcomes in the world on the use of proton therapy for post-operative prostate cancer. He previously served as the Senior GU Editor for the journal Advances in Radiation Oncology, and more recently as Deputy Editor for the International Journal of Radiation Oncology, Biology, Physics.

A renowned Oncologist, educator, and speaker, he has been a regularly invited commentator on CNN, CNN International, Fox News, NPR, and MSNBC/ MSNOW. He was awarded the American College of Radiation Oncology (ACRO) Media Award for Public Impact in 2025.

He recently completed his term of service on the American Society for Radiation Oncology's (ASTRO) Board of Directors as Chair of the Council on Healthcare Access and Engagement.

naspcc_program_Layout 1 10/30/2026 3:17 PM Page 13

FACULTY BIOS (continued)



James A. Eastham, MD
Chief of Urology
Department of Surgery
Memorial Sloan Kettering Cancer Center

James A. Eastham, MD, is a urologic oncologist who specializes in the treatment of prostate cancer. Dr. Eastham completed his undergraduate studies at the University of California, Irvine. He graduated from the University of Southern California (USC) Keck School of Medicine and completed his urology residence training at USC. His fellowship training in urologic oncology was at Baylor College of Medicine, Houston, Texas with Dr. Peter Scardino. He has been in academic practice for the past 30 years devoted exclusively to the care of men with prostate cancer. He currently is Chief of the Urology Service in the Department of Surgery at Memorial Sloan Kettering Cancer Center, Director of Clinical Research for the Urology Service, and Co-Leader of the Genitourinary Disease Management Team at MSK. Dr. Eastham holds the Peter T. Scardino Chair in Oncology at MSK. Dr. Eastham's primary research interests are in improving outcomes (such as cancer control, urinary continence, and sexual function) following surgery for prostate cancer and clinical correlations and biomarker analysis of prostate cancer.




Robert Ginyard
Host, "From Patient to Powerful Voice"

Robert Ginyard currently offers "From Patient to Powerful Voice" advocacy training to help patient advocates strengthen their communication, storytelling, and media-readiness skills. He helps them identify the larger universal human themes to connect with broader audiences and help drive change.



James L. Gulley, MD, PhD
Co-Director, Center for Immuno-Oncology, CCR, NCI
& Clinical Director, National Cancer Institute
National Institutes of Health

Dr. James Gulley is an internationally recognized cancer immunotherapy expert. He earned his MD/PhD at Loma Linda University and trained at Emory University and the National Cancer Institute (NCI). At NCI's Center for Cancer Research, he is Co-Director of Center for Immuno-Oncology, and the Clinical Director of the NCI. Dr. Gulley's group has led over 100 pioneering immunotherapy trials, and has developed dozens immunotherapy agents leading to 3 FDA approvals so far. He has authored over 350 publications which have been cited over 37,000 times. He serves as the President of the Society for Immunotherapy of Cancer; and serves on the scientific advisory board for both Stand Up to Cancer and the Parker Institute for Cancer Immunotherapy.



Vincent Laudone, MD
Emeritus Faculty,
Memorial Sloan Kettering Cancer Center

Dr. Vincent Laudone is a urologic oncologist and surgeon who retired in 2026 after a 45-year career in medicine. He worked at Hartford Hospital and the University of Connecticut, and for the last 18 years at Memorial Sloan Kettering Cancer Center (MSK). In Hartford, he was a founding member of the Connecticut Surgical Group, chairman of the Cancer Committee at Hartford Hospital, and a member of the Connecticut State Medical Examining Board. His clinical practice focused on urologic cancers, especially prostate cancer.

At MSK, he was instrumental in building the robotic surgery program in the Department of Surgery and served as the Chief of Surgery and then Medical Director of the Josie Robertson Surgery Center. Teaching students and fellows, and taking a holistic, approach to patient care, have been the hallmarks of his career.



Mark Markowski, MD, PhD
Assistant Professor, John Hopkins University

Dr. Mark Markowski is a medical oncologist at the Kimmel Cancer Center at Sibley Memorial Hospital, as well as an instructor in the Department of Oncology at Johns Hopkins University School of Medicine. Dr. Markowski participates in multidisciplinary clinics at Sibley and The Johns Hopkins Hospital, and sees patients in the genitourinary clinics of both hospitals. He is board-certified in medical oncology and internal medicine by the American Board of Internal Medicine. Dr. Markowski treats numerous types of cancers, with a specialty in prostate cancer.

Dr. Markowski earned his medical degree and PhD in tumor biology at Georgetown University School of Medicine. He completed a residency in internal medicine at Columbia University, followed by a medical oncology fellowship at Johns Hopkins Hospital. Dr. Markowski is a board member and secretary for the Genito-Urinary Multidisciplinary D.C. Regional Oncology Project (GUMDROP).

Dr. Markowski previously served as a research associate at the Lombardi Comprehensive Cancer Center at Georgetown University. His research interests focus on early phase drug development for prostate cancer, and anti-inflammatory agents and cancer incidence. Dr. Markowski is currently conducting research with funding from a Postdoctoral Training Award from the Department of Defense's Prostate Cancer Research Program, and a Young Investigator Award from the Prostate Cancer Foundation, which focuses on new treatment strategies for prostate cancer patients and credentialing these treatments for advancement to clinical trials.

naspcc_program_Layout 1 10/30/2026 3:17 PM Page 14

FACULTY BIOS (continued)



Jeff Michalski, MD
Vice Chair of Radiation Oncology at Washington University Medical School
Chair of Theranostics Sub-Committee for NRG
Medical Director of the Siteman Cancer Center Clinical Trial Office

Dr. Michalski is a prostate cancer specialist, Chair of the Theranostics Sub-Committee for NRG, and the Vice Chair of the Department of Radiation Oncology at Washington University Medical School. He serves as the medical director of the Siteman Cancer Center's Clinical Trial Office and has served as the Principal Investigator for the Radiation Therapy Oncology Group at Washington University. He earned his medical degree from the Medical College of Wisconsin in Milwaukee and completed his internship in internal medicine at Columbia-Presbyterian Medical Center in New York, and residency in radiation oncology at Mallinckrodt Institute of Radiology at Washington University School of Medicine in St. Louis.

Dr. Michalski's research interests include radiation dose escalation in the management of prostate cancer; precision radiation therapy to reduce toxicity in late neuro-cognitive effects in children with medulloblastoma; and assessment of quality of life in survivors of adult and childhood malignancies. He served as the Principal Investigator of the Advanced Technology Consortium (ATC) and coordinated Quality Assurance of radiation therapy trials in the cooperative group programs. As the leader of the RTOG ATIC, he established guidelines for participation of emerging technologies such as Intensity Modulated Radiation Therapy (IMRT), Stereotactic Body Radiation Therapy (SBRT) and Proton Beam Radiation Therapy (PBRT). He was instrumental in coordinating trials that involved advanced imaging, such as RTOG 0522 in head and neck cancer and stereotactic body radiation therapy in lung cancer, such as RTOG 0236. As the PI of the ATC, he coordinated quality assurance of clinical trials using PBRT for Massachusetts General Hospital, and MD Anderson Cancer Center. He served as Co-Principal Investigator on a joint contract with the Veteran's Administration Medical Centers and ASTRO to develop a system to provide continuous feedback on the progress, quality and safety of veterans' cancer therapy.




Peter Nelson, MD
Professor, Human Biology and Clinical Research Fred Hutchinson Cancer Center
Director of the Sloan Precision Oncology Institute

Peter Nelson, MD, is a physician scientist with a research and clinical focus centered on the pathobiology of prostate cancer. Dr. Nelson is a Professor in the Divisions of Human Biology and Clinical Research at the Fred Hutchinson Cancer Center and Director of the Sloan Precision Oncology Institute. He is a Professor in the Departments of Medicine, Genome Sciences and Pathology at the University of Washington. He co-leads the Fred Hutch NCI Comprehensive Cancer Center's Prostate Cancer Program and is PI of the Pacific Northwest Prostate Cancer SPORE. Dr. Nelson's research involves several domains relevant to prostate cancer development and treatment at the interface of basic and applied science. Areas of focus include studies of androgen receptor function as a lineage oncogene in prostate cancer; assessments of prostate cancer genomes and epigenomes with respect to gene regulation and therapeutic targets, and analyses of tumor microenvironments as mediators of treatment resistance.



Saul Priceman, PhD
Associate Professor in the Dept. of Medicine at USC, & Founding Director of the KSOM/Norris Center for Cancer Cellular Immunotherapy Research

Dr. Saul Priceman is an Associate Professor in the Department of Medicine at the Keck School of Medicine of USC, the Founding Director of the KSOM/Norris Center for Cancer Cellular Immunotherapy Research (CCCIR), and the Norman and Mary Pattiz Endowed Chair in Cancer Research. Over the last 14 years, his research has focused on T cell immunobiology and cancer immunotherapies. Dr. Priceman's laboratory develops engineered T cell therapies and combinatorial approaches for the treatment of solid tumors, bringing several therapies to phase 1 clinical testing for patients with prostate cancer, breast cancer brain metastasis, and ovarian cancer. His research has led to high-impact publications and numerous patents and technologies licensed for further clinical development. Dr. Priceman's research has been funded with grants from the National Cancer Institute, the Department of Defense, the California Institute for Regenerative Medicine, and the Prostate Cancer Foundation. He received his B.S. in microbiology from the University of California, Santa Barbara, his Ph.D. in molecular and medical pharmacology from the University of California, Los Angeles, and completed his postdoctoral fellowship at the City of Hope.



Paul Schellhammer, MD
Professor Emeritus, Urology,
Joan and Macon Brock Health Science Center, East Virginia Medical Center, Norfolk, Virginia

Dr. Paul Schellhammer received his undergraduate education at the University of Notre Dame and his medical school training and Cornell Medical College in New York City. His surgical and urologic training were taken at the University Hospital of Cleveland in Cleveland, Ohio and the Medical College of Virginia, Richmond, Virginia. This was followed by a fellowship in urologic oncology at Memorial Sloan Kettering Cancer Center in New York. Subsequently he joined the practice of Devine Poutasse Fiveash Urology (Urology of Virginia) and became a faculty member of Eastern Virginia Medical School where he eventually achieved the rank of Professor and then also served as Chairman of the Department of Urology and Program Director of the Resident Training Program.

Dr. Schellhammer has served as a medical officer in Viet Nam, as a Trustee of the American Board of Urology and as its President. He has also served as President of the Society of Urologic Oncology, as President of his Mid-Atlantic Section of the American Urologic Association, as a member of the Board of Directors of the American Urologic Association, and President of the American Urologic Association 2007-2008.

naspcc_program_Layout 1 10/30/2026 3:17 PM Page 15

FACULTY BIOS (continued)



Joseph E. Scherger, MD, MPH
Founder & Medical Director of
Restore Health Disease Reversal

Joseph E. Scherger, M.D., M.P.H., is founder and medical director of Restore Health Disease Reversal, a concierge primary care and consultation practice based in Indian Wells, Ca. He is a core faculty in the Eisenhower Health Family Medicine Residency program based in La Quinta, CA. Dr. Scherger is Clinical Professor of Family Medicine at the Keck School of Medicine at the University of Southern California (USC), Loma Linda University and the University of California, Riverside School of Medicine. Dr. Scherger has special interests in nutrition and using lifestyle change to reverse disease. He is the author of four books, 40 Years in Family Medicine (2014), Lean and Fit: A Doctor's Journey to Healthy Nutrition and Greater Wellness (Third Edition, 2019) and Restore Health: Disease Reversal (2024), and 50 Years in Family Medicine (2025). He is the Medical Director of the anti-aging company Intervene Immune.

Dr. Scherger graduated from the UCLA School of Medicine in 1975 and completed a Family Medicine Residency and a Masters in Public Health at the University of Washington in 1978. From 1992-1996, he was Vice President for Family Practice and Primary Care Education at Sharp HealthCare in San Diego. From 1996-2001, he was the Chair of the Department of Family Medicine and the Associate Dean for Primary Care at the University of California Irvine. From 2001-2003, Dr. Scherger served as founding dean of the Florida State University College of Medicine. He served as Vice President for Primary Care (2009-2018) and Chair of Graduate Medical Education (2009-2015) at Eisenhower Medical Center in Rancho Mirage, CA.

Dr. Scherger has received numerous awards, including being voted as the Outstanding Clinical Instructor at the University of California, Davis School of Medicine in 1984, 1989 and 1990. In 1989, he was Family Physician of the Year by the American Academy of Family Physicians and the California Academy of Family Physicians. In 1992, Dr. Scherger was elected to the National Academy of Medicine (Institute of Medicine) of the National Academy of Sciences. In 2016 Dr. Scherger received the Desert Health Integrative Practitioner Wellness Award. He was the 2017 President of the Riverside County Medical Association. In 2019 Dr. Scherger was elected to the Bishop Society of the Society of Teachers of Family Medicine.

Dr. Scherger served on the Board of Directors of the American Academy of Family Physicians and the American Board of Family Medicine. He currently serves on the editorial advisory board of Medical Economics.

Dr. Scherger has authored over 1100 medical publications and has given over 1100 invited presentations. He has also competed in 40 marathons, ten 50K, and 5 50-mile ultramarathon trail runs; and is now a dedicated walker.



Bilal A Siddiqui, MD
Assistant Professor,
Department of Genitourinary Medical Oncology
University of Texas MD Anderson Cancer Center

Dr. Siddiqui is an Assistant Professor in Genitourinary Medical Oncology at the University of Texas MD Anderson. He is a clinical and translational investigator with a focus on :1) biomarker-rich trials of immunotherapies in prostate cancer, with a special emphasis on T cell engagers; and 2) improving outcomes in immune-mediated toxicities through identification of mechanistic biomarkers for early detection and rational intervention. He serves as a principal investigator on multiple clinical trials of T cell engagers in prostate cancer, including leading multicenter sponsored trials and investigator-initiated studies. He is the Co-Chair of the MD Anderson IOTOX Leaders' Group and Chair of the GU IOTOX Steering Committee. The long-term goals of his work is to maximize efficacy and minimize toxicities of these immunotherapy strategies in patients.



Sumit Subudhi, MD
Associate Professor,
Department of Genitourinary Medical Oncology,
University of Texas MD Anderson Cancer Center

Sumit Subudhi is an Associate Professor in the Department of Genitourinary Medical Oncology at The University of Texas MD Anderson Cancer Center. As a trained medical oncologist and immunologist, he serves as the principal investigator of multiple biomarker-rich clinical trials evaluating immune checkpoint therapies, bispecific T-cell engagers, and vaccines. His translational research focuses on investigating the immunological mechanisms mediating anti-tumor responses and therapy-related toxicities with the ultimate goal of maximizing efficacy and minimizing toxicities for patients with advanced prostate cancer. He also served as lead PI for Prostate Researching Translational Endpoints Correlated to Response (PORTER) clinical trials to inform use of novel combinations, which were sponsored by Parker Institute of Cancer Immunotherapy (PICI) and Cancer Research Institute (CRI). His work has led to the identification of mechanisms associated with resistance to immunotherapies and candidate biomarkers of responses to these approaches.



Scott T. Tagawa, MD, MS, FASCO, FACP
Lebroe Family Professor of Hematology-Oncology and Professor of Medicine in Urology at Weill Cornell Medicine,
Attending Physician at New York Presbyterian

Scott T. Tagawa, MD, MS, FASCO, FACP is the Lebroe Family Professor of Hematology-Oncology and Professor of Medicine in Urology at Weill Cornell Medicine, and an Attending Physician at New York-Presbyterian – Weill Cornell Medical Center. After earning his BS from Georgetown University, Dr. Tagawa received his MD at the University of Southern California School of Medicine, also completing Internship, Residency, and fellowship training there. Following an appointment as Assistant Professor of Medicine at Mount Sinai School of Medicine, he was recruited to Weill Cornell Medical College in 2007. As the Medical Director of the Genitourinary Oncology Research Program, Dr. Tagawa leads clinical trials in the areas of prostate, bladder, and kidney cancer as well as the prevention and treatment of thrombosis with cancer. He specializes in drug development in GU malignancies with a particular interest cell-surface targeting, including prostate-specific membrane antigen (PSMA) theranostics. Dr. Tagawa serves as the WCM principal investigator for the Alliance for Clinical Trials in Oncology (formerly CALGB), serving on the Board of Directors and as a funded member of the Genitourinary Committee. He has served on multiple committees for the American Society of Clinical Oncology (currently a member of the GU Guideline Advisory Group and co-chair of the metastatic androgen pathway modulation naïve/sensitive prostate cancer guideline panel) and has been awarded Fellowship in ASCO. Additionally, he serves on the editorial boards of many journals, is a member of numerous national and international medical and scientific societies, and has been named on multiple "top doctor" award lists.

naspcc_program_Layout 1 10/30/2026 3:17 PM Page 16

FACULTY BIOS (continued)



Mark Vieth
Senior Vice President, CRD Associates
Mark D. Vieth, Senior Vice President, joined the firm in 2002 and manages a diverse portfolio of clients in several practice areas, including public health and medical research. Mark currently serves as the coordinator for several national coalitions, including the Defense Health Research Consortium. He has specialized in bringing diverse associations, foundations, institutions of higher education and other stakeholders together to advocate for common objectives. He has helped clients secure federal funding, build new partnerships with federal agencies and mobilize grassroots to advocate for legislation pending in Congress. He also has developed a niche in helping clients who have never interacted with Congress or federal agencies launch sophisticated and focused federal government relations strategies.

Prior to joining CRD Associates, Mark served for 14 years as a professional staff member in the House of Representatives. As Chief of Staff for Congressman Robert A. Borski (D-PA), Mark worked extensively on legislative issues and projects of importance to one of the nation's major medical research clusters in Philadelphia. Mark is also past President and current Treasurer of the Pennsylvania Society of Washington, D.C. He earned his B.A. in international relations from Syracuse University.



Jeremiah Wala, MD, PhD
Clinical and Translational Investigator at Dana-Farber Cancer Institute and an Instructor in Medicine at Harvard Medical School
Jeremiah Wala, MD, PhD, is a Clinical and Translational Investigator at Dana-Farber Cancer Institute and an Instructor in Medicine at Harvard Medical School. He is a medical oncologist with a clinical focus on genitourinary cancers. His laboratory studies the spatial organization of the tumor immune microenvironment using multiplexed tissue imaging and computational pathology, with a focus on traditionally immune cold and copy-number driven tumors like prostate cancer. He completed his MD-PhD at Harvard where he developed algorithms for structural variation analysis in cancer genomes. He completed internal medicine residency at UCSF and medical oncology fellowship at Dana-Farber.

22nd ANNIVERSARY
NASPCC
National Alliance of State Prostate Cancer Coalitions

EUROPA UOMO
The Voice of Men with Prostate Cancer in Europe

Birth of a World Prostate Cancer: IUPCC

Based upon discussions that Merel Nissenberg, President of NASPCC, and Erik Briers, Chairman of Europa Uomo, held in March of this year at the EAU Meeting, it was agreed that both organizations would aim to help patients worldwide by spearheading the development of a new world prostate cancer coalition. Europa Uomo is the European Prostate Cancer Coalition and is comprised of 31 organizations across Europe.

On May 31 this year during ASCO, NASPCC and Europa Uomo convened a Roundtable at the Swissotel in Chicago attended by 35 participants, to discuss the need and the desire to form such an organization. Specifically, the question was asked: do we need and do we want this? Are there unmet needs in other countries, on other continents? Some of the participants were from Prostate Cancer UK, Movember, Prostate Cancer Foundation, ZERO, Prostate Cancer Research UK, and an oncology group from Brazil in South America. To a person all said they thought this was a good idea, and we agreed that we will have several follow-up discussions with organizations from around the world over the next several months, especially during the EAU Meeting next March. We need specifics, what needs to address, how to go about that, what form of governance, and the like. Erik Briers suggests that we might call this the International Union of Prostate Cancer Coalitions (IUCCC).

It is very exciting to be at the forefront of what will help so many patients and their families, around the globe!

naspcc_program_Layout 1 10/30/2026 3:17 PM Page 17

22nd ANNIVERSARY

NASPCC

National Alliance of State Prostate Cancer Coalitions

NASPCC would like to thank the following for their sponsorship or support in making this Annual Meeting a reality

SHIPLEY FOUNDATION, INC.

AMGEN

NOVARTIS

Pfizer

BIONTECH

LANTHEUS™

AstraZeneca

Johnson & Johnson

BAYER Bayer

Dendreon

BLUE EARTH DIAGNOSTICS
A Bracco Company

MERCK
INVENTING FOR LIFE

FOUNDATION MEDICINE

Telix

EXELIXIS®

Avenda Health